生产企业：Lynk Pharmaceuticals (originator), Formation Bio / Bleecker Bio (developer, ex-Greater China)
LNK-01006 (now BLKR201) was originally discovered by Lynk Pharmaceuticals, a clinical-stage innovative drug company founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and TYK2 signaling pathways. In December 2025, Lynk Pharmaceuticals entered into an exclusive development and licensing agreement with Formation Bio's subsidiary Bleecker Bio for LNK-01006 outside Greater China. Under the terms, Lynk Pharmaceuticals received a minority equity stake in Bleecker Bio, an upfront payment, and is eligible for additional development, regulatory, and commercial milestones totaling up to $605 million, plus tiered royalties on potential future sales. Formation Bio advanced the asset from deal close to first participant dosed in a Phase 1 trial in five months.
LNK-01006 (now BLKR201) was originally discovered by Lynk Pharmaceuticals, a clinical-stage innovative drug company founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and TYK2 signaling pathways. In December 2025, Lynk Pharmaceuticals entered into an exclusive development and licensing agreement with Formation Bio's subsidiary Bleecker Bio for LNK-01006 outside Greater China. Under the terms, Lynk Pharmaceuticals received a minority equity stake in Bleecker Bio, an upfront payment, and is eligible for additional development, regulatory, and commercial milestones totaling up to $605 million, plus tiered royalties on potential future sales. Formation Bio advanced the asset from deal close to first participant dosed in a Phase 1 trial in five months.
BLKR201/LNK-01006 is a CNS-penetrant allosteric TYK2 inhibitor designed to regulate immune signaling within the central nervous system. TYK2 is a validated target with an established clinical safety profile, and the CNS exposure and high target selectivity of this compound may open up indications where central or compartmentalized immune pathways are believed to drive disease.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
